Literature DB >> 28340332

Super elongation complex promotes early HIV transcription and its function is modulated by P-TEFb.

Alona Kuzmina1, Simona Krasnopolsky1, Ran Taube1.   

Abstract

Early work on the control of transcription of the human immunodeficiency virus (HIV) laid the foundation for our current knowledge of how RNA Polymerase II is released from promoter-proximal pausing sites and transcription elongation is enhanced. The viral Tat activator recruits Positive Transcription Elongation Factor b (P-TEFb) and Super Elongation Complex (SEC) that jointly drive transcription elongation. While substantial progress in understanding the role of SEC in HIV gene transcription elongation has been obtained, defining of the mechanisms that govern SEC functions is still limited, and the role of SEC in controlling HIV transcription in the absence of Tat is less clear. Here we revisit the contribution of SEC in early steps of HIV gene transcription. In the absence of Tat, the AF4/FMR2 Family member 4 (AFF4) of SEC efficiently activates HIV transcription, while gene activation by its homolog AFF1 is substantially lower. Differential recruitment to the HIV promoter and association with Human Polymerase-Associated Factor complex (PAFc) play key role in this functional distinction between AFF4 and AFF1. Moreover, while depletion of cyclin T1 expression has subtle effects on HIV gene transcription in the absence of Tat, knockout (KO) of AFF1, AFF4, or both proteins slightly repress this early step of viral transcription. Upon Tat expression, HIV transcription reaches optimal levels despite KO of AFF1 or AFF4 expression. However, double AFF1/AFF4 KO completely diminishes Tat trans-activation. Significantly, our results show that P-TEFb phosphorylates AFF4 and modulates SEC assembly, AFF1/4 dimerization and recruitment to the viral promoter. We conclude that SEC promotes both early steps of HIV transcription in the absence of Tat, as well as elongation of transcription, when Tat is expressed. Significantly, SEC functions are modulated by P-TEFb.

Entities:  

Keywords:  RNA polymerase II; Tat trans-activator; eukaryotic transcription; human immunodeficiency virus (HIV); positive transcription elongation factor b (P-TEFb); super elongation complex (SEC); transcription elongation

Mesh:

Substances:

Year:  2017        PMID: 28340332      PMCID: PMC5501376          DOI: 10.1080/21541264.2017.1295831

Source DB:  PubMed          Journal:  Transcription        ISSN: 2154-1272


  60 in total

1.  Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase.

Authors:  J B Kim; P A Sharp
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

2.  Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription.

Authors:  Malini Natarajan; Gillian M Schiralli Lester; Chanhyo Lee; Anamika Missra; Gregory A Wasserman; Martin Steffen; David S Gilmour; Andrew J Henderson
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

Review 3.  The super elongation complex (SEC) family in transcriptional control.

Authors:  Zhuojuan Luo; Chengqi Lin; Ali Shilatifard
Journal:  Nat Rev Mol Cell Biol       Date:  2012-08-16       Impact factor: 94.444

4.  HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription.

Authors:  Nanhai He; Min Liu; Joanne Hsu; Yuhua Xue; Seemay Chou; Alma Burlingame; Nevan J Krogan; Tom Alber; Qiang Zhou
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

Review 5.  The control of HIV transcription: keeping RNA polymerase II on track.

Authors:  Melanie Ott; Matthias Geyer; Qiang Zhou
Journal:  Cell Host Microbe       Date:  2011-11-17       Impact factor: 21.023

6.  Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes.

Authors:  Sebastian Schröder; Sungyoo Cho; Lei Zeng; Qiang Zhang; Katrin Kaehlcke; Lily Mak; Joann Lau; Dwayne Bisgrove; Martina Schnölzer; Eric Verdin; Ming-Ming Zhou; Melanie Ott
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

7.  BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.

Authors:  Daniela Boehm; Vincenzo Calvanese; Roy D Dar; Sifei Xing; Sebastian Schroeder; Laura Martins; Katherine Aull; Pao-Chen Li; Vicente Planelles; James E Bradner; Ming-Ming Zhou; Robert F Siliciano; Leor Weinberger; Eric Verdin; Melanie Ott
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

8.  Defining the status of RNA polymerase at promoters.

Authors:  Leighton J Core; Joshua J Waterfall; Daniel A Gilchrist; David C Fargo; Hojoong Kwak; Karen Adelman; John T Lis
Journal:  Cell Rep       Date:  2012-10-10       Impact factor: 9.423

9.  AFF1 is a ubiquitous P-TEFb partner to enable Tat extraction of P-TEFb from 7SK snRNP and formation of SECs for HIV transactivation.

Authors:  Huasong Lu; Zichong Li; Yuhua Xue; Ursula Schulze-Gahmen; Jeffrey R Johnson; Nevan J Krogan; Tom Alber; Qiang Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

10.  Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein.

Authors:  Koen Bartholomeeusen; Yanhui Xiang; Koh Fujinaga; B Matija Peterlin
Journal:  J Biol Chem       Date:  2012-09-05       Impact factor: 5.157

View more
  9 in total

1.  Structure of the super-elongation complex subunit AFF4 C-terminal homology domain reveals requirements for AFF homo- and heterodimerization.

Authors:  Ying Chen; Patrick Cramer
Journal:  J Biol Chem       Date:  2019-05-30       Impact factor: 5.157

2.  AFF4 regulates osteogenic differentiation of human dental follicle cells.

Authors:  Qingyue Xiao; Yuning Zhang; Xingying Qi; Yaqian Chen; Rui Sheng; Ruoshi Xu; Quan Yuan; Chenchen Zhou
Journal:  Int J Oral Sci       Date:  2020-06-30       Impact factor: 6.344

Review 3.  HIV Tat/P-TEFb Interaction: A Potential Target for Novel Anti-HIV Therapies.

Authors:  Kaori Asamitsu; Koh Fujinaga; Takashi Okamoto
Journal:  Molecules       Date:  2018-04-17       Impact factor: 4.411

4.  Fused in sarcoma silences HIV gene transcription and maintains viral latency through suppressing AFF4 gene activation.

Authors:  Simona Krasnopolsky; Lital Marom; Rachel A Victor; Alona Kuzmina; Jacob C Schwartz; Koh Fujinaga; Ran Taube
Journal:  Retrovirology       Date:  2019-06-25       Impact factor: 3.768

Review 5.  Key Players in HIV-1 Transcriptional Regulation: Targets for a Functional Cure.

Authors:  Luisa Mori; Susana T Valente
Journal:  Viruses       Date:  2020-05-11       Impact factor: 5.048

6.  Structural and functional insight into the effect of AFF4 dimerization on activation of HIV-1 proviral transcription.

Authors:  Dan Tang; Chunjing Chen; Ga Liao; Jiaming Liu; Banghua Liao; QingQing Huang; Qianqian Chen; Jiahui Zhao; Hui Jiang; Jinsong Duan; Jin Huang; Kunjie Wang; Jiawei Wang; Cuiyan Zhou; Wendan Chu; Wenqi Li; Bo Sun; Zhonghan Li; Lunzhi Dai; Xianghui Fu; Wei Cheng; Yuhua Xue; Shiqian Qi
Journal:  Cell Discov       Date:  2020-02-18       Impact factor: 10.849

Review 7.  Role of RNA Polymerase II Promoter-Proximal Pausing in Viral Transcription.

Authors:  Marilyn Whelan; Martin Pelchat
Journal:  Viruses       Date:  2022-09-13       Impact factor: 5.818

Review 8.  CDK9 keeps RNA polymerase II on track.

Authors:  Sylvain Egloff
Journal:  Cell Mol Life Sci       Date:  2021-06-19       Impact factor: 9.261

9.  A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.

Authors:  Edward K Maina; Asma A Adan; Haddison Mureithi; Joseph Muriuki; Raphael M Lwembe
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.581

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.